Biomarin hopes to have a European approval of its potential new drug for the treatment of severe hemophilia A before summer 2022, the company reports in a press release in connection with its third quarter results.
Biomarin Chair and Chief Executive Jean-Jacques Bienaimé also promises to present data from the company's ongoing phase III trial with Valoctocogene Roxaparvovec in the beginning of 2022.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.